Antriabio Inc (ANTB) 1.5500 $ANTB
AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions
Marketwired - Mon May 11, 7:02AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced today that it will be presenting data for its lead product candidate, AB101, on Saturday, June 6, 2015 at the American Diabetes Association 75th Scientific Sessions® in Boston. The abstract, accepted for oral presentation, will include results from preclinical in vitro and in vivo pharmacology studies of AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes.
AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development
Marketwired - Thu Jan 08, 6:35AM CST
AntriaBio, Inc. ("AntriaBio or the "Company" (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that Dr. Hoyoung Huh, one of the Company's co-founders and member of the Board of Directors will expand his role to Chair the Company's business development efforts, product pipeline strategy, and Scientific Advisory Board.
AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species
Marketwired - Wed Jan 07, 7:02AM CST
AntriaBio, Inc. ("AntriaBio or the "Company" (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully completed a series of in vitro and multi-species animal pharmacology studies for AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes. The studies assessed the receptor pharmacology, pharmacokinetics and pharmacodynamics of AB101 and support potential proof-of-concept for a once-weekly basal insulin in patients. The current standard of care in the $10 billion basal insulin market is a daily treatment.
AntriaBio Announces $7 Million Private Placement
Marketwired - Mon Jan 05, 6:35AM CST
AntriaBio, Inc. ("Company" (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully raised approximately $7 million in a private placement transaction. At $1.85 per unit, institutions and accredited investors were issued one share of common stock and one warrant exercisable for three years at $2.50 for one share of common stock. Notably, the Company was successful in raising over $18 million through equity financings in 2014.
AntriaBio Extinguishes $44 Million Contingent Liability
Marketwired - Mon Nov 10, 7:06AM CST
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully extinguished $44 million of contingent milestone payments owed by AntriaBio to the bankruptcy estate of PR Pharmaceuticals, Inc. (the "Estate".
AntriaBio, Inc. - "Big Pharma Strategic Partnerships"
ACCESSWIRE - Wed Aug 20, 9:10AM CDT
New York, NY / ACCESSWIRE / August 20, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Mr. Nevan Elam. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
AntriaBio, Inc. - "Expanding the Treatment Options"
ACCESSWIRE - Mon Aug 04, 8:41AM CDT
New York, NY / August 4, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman's Blog, written by the Company's VP of Clinical Development, Dr. Brian Roberts. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
AntriaBio Appoints Barry Sherman, M.D. to Its Board of Directors
Marketwire - Wed Jul 23, 6:35AM CDT
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel therapeutics to treat patients with diabetes and metabolic diseases, announced today the appointment of Barry Sherman, M.D. to its Board of Directors.
AntriaBio, Inc. - "An Update on Basal Insulins from ADA"
ACCESSWIRE - Wed Jun 25, 9:37AM CDT
New York, NY / June 25, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Mr. Nevan Elam. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
AntriaBio Appoints C. Ronald Kahn, M.D. to Its Scientific Advisory Board
Marketwire - Mon Jun 23, 6:35AM CDT
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel therapeutics to treat patients with diabetes and metabolic diseases, announced the appointment of C. Ronald Kahn, M.D. to its Scientific Advisory Board (SAB).
AntriaBio, Inc. "The â??Smart Science' Behind AB101"
ACCESSWIRE - Wed Jun 18, 7:32AM CDT
New York, NY / June 18, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Mr. Nevan Elam. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions
Marketwired - Mon May 11, 7:02AM CDT
AntriaBio, Inc. ("AntriaBio" or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation developing novel extended release therapies, announced today that it will be presenting data for its lead product candidate, AB101, on Saturday, June 6, 2015 at the American Diabetes Association 75th Scientific Sessions® in Boston. The abstract, accepted for oral presentation, will include results from preclinical in vitro and in vivo pharmacology studies of AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes. AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development
Marketwired - Thu Jan 08, 6:35AM CST
AntriaBio, Inc. ("AntriaBio or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that Dr. Hoyoung Huh, one of the Company's co-founders and member of the Board of Directors will expand his role to Chair the Company's business development efforts, product pipeline strategy, and Scientific Advisory Board. AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species
Marketwired - Wed Jan 07, 7:02AM CST
AntriaBio, Inc. ("AntriaBio or the "Company"
(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully completed a series of in vitro and multi-species animal pharmacology studies for AB101, a potential once-weekly basal insulin being developed for patients with type 1 and type 2 diabetes. The studies assessed the receptor pharmacology, pharmacokinetics and pharmacodynamics of AB101 and support potential proof-of-concept for a once-weekly basal insulin in patients. The current standard of care in the $10 billion basal insulin market is a daily treatment. AntriaBio Announces $7 Million Private Placement
Marketwired - Mon Jan 05, 6:35AM CST
AntriaBio, Inc. ("Company"
(OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully raised approximately $7 million in a private placement transaction. At $1.85 per unit, institutions and accredited investors were issued one share of common stock and one warrant exercisable for three years at $2.50 for one share of common stock. Notably, the Company was successful in raising over $18 million through equity financings in 2014. AntriaBio Extinguishes $44 Million Contingent Liability
Marketwired - Mon Nov 10, 7:06AM CST
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully extinguished $44 million of contingent milestone payments owed by AntriaBio to the bankruptcy estate of PR Pharmaceuticals, Inc. (the "Estate"
. AntriaBio, Inc. - "Big Pharma Strategic Partnerships"
ACCESSWIRE - Wed Aug 20, 9:10AM CDT
New York, NY / ACCESSWIRE / August 20, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Mr. Nevan Elam. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
AntriaBio, Inc. - "Expanding the Treatment Options"
ACCESSWIRE - Mon Aug 04, 8:41AM CDT
New York, NY / August 4, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman's Blog, written by the Company's VP of Clinical Development, Dr. Brian Roberts. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
AntriaBio Appoints Barry Sherman, M.D. to Its Board of Directors
Marketwire - Wed Jul 23, 6:35AM CDT
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel therapeutics to treat patients with diabetes and metabolic diseases, announced today the appointment of Barry Sherman, M.D. to its Board of Directors.
AntriaBio, Inc. - "An Update on Basal Insulins from ADA"
ACCESSWIRE - Wed Jun 25, 9:37AM CDT
New York, NY / June 25, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Mr. Nevan Elam. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
AntriaBio Appoints C. Ronald Kahn, M.D. to Its Scientific Advisory Board
Marketwire - Mon Jun 23, 6:35AM CDT
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel therapeutics to treat patients with diabetes and metabolic diseases, announced the appointment of C. Ronald Kahn, M.D. to its Scientific Advisory Board (SAB).
AntriaBio, Inc. "The â??Smart Science' Behind AB101"
ACCESSWIRE - Wed Jun 18, 7:32AM CDT
New York, NY / June 18, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Mr. Nevan Elam. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
